New Data Support Long-term Efficacy, Safety of Isturisa
Treatment with Isturisa (osilodrostat) normalized urine cortisol levels up to nearly 1.5 years in people with Cushing’s disease, according to data from the Phase 3 LINC-4 clinical trial. Data from another Phase 3 trial, LINC-3 (NCT02180217), showed that testosterone levels were generally stable among Cushing’s patients treated with…